Synaffix BV
Platform technology enabling best-in-class antibody-drug conjugates and bispecific antibodies
Formed in 2010, Synaffix is a Netherlands-based biotechnology company exclusively focused on continued advancement of a best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, the vision of Synaffix is to become the preferred partner in the development of these complex biological therapeutics and realize its ambition - connect to cure.
Synaffix was acquired by Lonza in 2023.